IL207835A0 - Methods for treating disorders using nmda nr2b-subtype selective antagonist - Google Patents

Methods for treating disorders using nmda nr2b-subtype selective antagonist

Info

Publication number
IL207835A0
IL207835A0 IL207835A IL20783510A IL207835A0 IL 207835 A0 IL207835 A0 IL 207835A0 IL 207835 A IL207835 A IL 207835A IL 20783510 A IL20783510 A IL 20783510A IL 207835 A0 IL207835 A0 IL 207835A0
Authority
IL
Israel
Prior art keywords
methods
treating disorders
selective antagonist
subtype selective
nmda nr2b
Prior art date
Application number
IL207835A
Other languages
English (en)
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Publication of IL207835A0 publication Critical patent/IL207835A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL207835A 2008-03-27 2010-08-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist IL207835A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4008708P 2008-03-27 2008-03-27
PCT/EP2009/002241 WO2009118187A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Publications (1)

Publication Number Publication Date
IL207835A0 true IL207835A0 (en) 2010-12-30

Family

ID=40910288

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207835A IL207835A0 (en) 2008-03-27 2010-08-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Country Status (14)

Country Link
US (1) US20110053951A1 (enExample)
EP (1) EP2254580A1 (enExample)
JP (3) JP2011516417A (enExample)
KR (1) KR20100135847A (enExample)
CN (1) CN101977606A (enExample)
AU (1) AU2009228660B2 (enExample)
BR (1) BRPI0909378A2 (enExample)
CA (1) CA2719749A1 (enExample)
IL (1) IL207835A0 (enExample)
MX (1) MX2010009649A (enExample)
NZ (1) NZ588698A (enExample)
RU (1) RU2499598C2 (enExample)
WO (1) WO2009118187A1 (enExample)
ZA (1) ZA201006587B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
WO2015175806A1 (en) 2014-05-16 2015-11-19 The Trustees Of The University Of Pennsylvania Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models
JP6605020B2 (ja) 2014-08-15 2019-11-13 ヤンセン ファーマシューティカルズ,インコーポレーテッド Nr2b受容体阻害剤としてのトリアゾール
HUE049278T2 (hu) 2014-08-15 2020-09-28 Janssen Pharmaceuticals Inc Pirazolok
CN107849010B (zh) 2015-06-01 2021-11-09 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物
SMT202000134T1 (it) 2015-07-09 2020-05-08 Janssen Pharmaceutica Nv 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US10732235B2 (en) * 2018-03-29 2020-08-04 Siemens Healthcare Gmbh Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
US11618750B2 (en) 2019-06-14 2023-04-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801774T2 (xx) * 1996-03-08 1998-12-21 F.Hoffmann-La Roche Ag 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
DK1070708T3 (da) * 1999-07-21 2004-05-10 Hoffmann La Roche Triazolderivater
EP1278728B1 (en) * 2000-04-20 2004-08-25 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2001296994A1 (en) * 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1915624A1 (en) * 2005-07-29 2008-04-30 Regents of the University of Minnesota Amyloid beta receptor and uses thereof

Also Published As

Publication number Publication date
JP2011516417A (ja) 2011-05-26
WO2009118187A1 (en) 2009-10-01
MX2010009649A (es) 2010-12-17
ZA201006587B (en) 2012-02-29
CA2719749A1 (en) 2009-10-01
AU2009228660A1 (en) 2009-10-01
JP2016094430A (ja) 2016-05-26
NZ588698A (en) 2012-06-29
BRPI0909378A2 (pt) 2015-10-06
AU2009228660B2 (en) 2012-11-29
JP2014098018A (ja) 2014-05-29
RU2499598C2 (ru) 2013-11-27
US20110053951A1 (en) 2011-03-03
EP2254580A1 (en) 2010-12-01
KR20100135847A (ko) 2010-12-27
CN101977606A (zh) 2011-02-16
RU2010143864A (ru) 2012-05-10

Similar Documents

Publication Publication Date Title
IL207835A0 (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
IL212986A0 (en) Methods for treating eye disorders
IL257418A (en) Methods for treating addiction
IL248652A0 (en) Methods, compositions and devices for facilitating re-creation
GB2456192B (en) Dust-separating apparatus
ZA201001753B (en) Method for consumer-dispenser interactions
TWI372600B (en) Apparatus for cutting noodle
GB2467710B (en) Methods for treating social disorders
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
IL213476A0 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
GB0819934D0 (en) Transactional apparatus
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
EP2382071A4 (en) METHODS OF CLEANING DIES
HUE037314T2 (hu) Vágóberendezés
EP2248810A4 (en) METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE
PL2229430T3 (pl) Sposób wytwarzania węglowodorów
IL205432A0 (en) Method of identigfying safe nmda receptor antagonists
IL205535A0 (en) S- alkylisothiouronium derivatives for treating uterine hypercontractility disorders
EP2323989A4 (en) METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
IL208768A0 (en) Methods for radiolabelling macromolecules
IL207906A0 (en) Treatment for ocular-related disorders
TWI368170B (en) Interruption-based concurrent profiling method
GB0812144D0 (en) Cutting apparatus
HK1150761A (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist